[ad_1]
Hangzhou, China and Shaoxing, China, January 9, 2022 /PRNewswire/ – Ascletis Pharma Inc. (HKEX: 1672) today announced the submission of a US Investigational New Drug (IND) application for the internally developed oral PD-L1 small molecule inhibitor ASC61 for the treatment of advanced solid tumors.
ASC61 is an oral potent and highly selective PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing PD-L1 dimerization and internalization. As a single agent, ASC61 has shown significant anti-tumor efficacy in a variety of animal models (such as humanized mouse models). Preclinical studies have shown that ASC61 has good safety and pharmacokinetic characteristics in animal models. The ASC61 oral tablet that will be used in clinical trials is developed using in-house proprietary technology.
Compared with PD-1/PD-L1 antibody for injection, ASC61, as an oral PD-L1 inhibitor, has the following advantages: (1) Convenient administration and no hospitalization required for injection; (2) Comparing with other oral anti-tumor drugs Oral combination medication; (3) Quickly adjust the dose to better manage immune-related adverse events (irAE).
“We are very pleased to submit the US IND for ASC61.” said the doctor. Jinzi J. Wu, …
The full story can be found on Benzinga.com
[ad_2]
Source link
